Kanavos, Panos

Number of items: 268.
Article
  • Candore, Gianmario, Martin, Claire, Mills, Mackenzie J., Suter, Annabel, Lloyd, Anna, Chavez‐Montoya, Danitza, Civitelli, Diego, Wolf, Birgit, Bolot, Paul & Wasem, Juergen et al (2026). Reply to "On selection and analytical transparency in the FRAME Framework for RWE evaluation". Clinical Pharmacology and Therapeutics, https://doi.org/10.1002/cpt.70197
  • Therianos, Panagiotis, Miracolo, Aurelio, Gill, Jennifer, Kanavos, Panos (2025). CO109 Evaluating the lifetime incremental value of pharmaceutical innovation: the case of non-small cell lung cancer. Value in Health, 28(12, Supplement 1), S63. https://doi.org/10.1016/j.jval.2025.09.211
  • Al-Omar, Hussain Abdulrahman, Al-Muhsin, Asma Abdulaziz, Almudaiyan, Lolwa, Hassan Al-Najjar, Amal, Abu Esba, Laila Carolina, Almodaimegh, Hind, Altawil, Esraa, Yousef, Consuela, Khan, Mansoor & AlYahya, Khalid et al (2025). HPR10 A strategic national framework for managed entry agreements to access innovative and breakthrough medications in Saudi Arabia. Value in Health, 28(12, Supplement 1), S323. https://doi.org/10.1016/j.jval.2025.09.1420
  • Civitelli, Diego, Kanavos, Panos (2025). HPR2 A case study: how England implemented its first Population Health Agreement. Value in Health, 28(12, Supplement 1), S321. https://doi.org/10.1016/j.jval.2025.09.1412
  • Chavez, Danitza, Kanavos, Panos (2025). HPR40 Building risk-sharing agreements in Chile: feasibility and policy options. Value in Health, 28(12, Supplement 1), S329. https://doi.org/10.1016/j.jval.2025.09.1450
  • Gill, Jennifer, Chavez, Danitza, Main, Caitlin, Satish, Kavyashree, Kanavos, Panos (2025). HSD13 Barriers and enablers in health system redesign. Value in Health, 28(12, Supplement 1), S375. https://doi.org/10.1016/j.jval.2025.09.1674
  • McIntyre, Finlay, Lin, Ryan, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA155 From license to reimbursement: a slot-based ML framework for seamless MA to HTA alignment. Value in Health, 28(12, Supplement 1), S433 - S434. https://doi.org/10.1016/j.jval.2025.09.1940
  • Civitelli, Diego, Therianos, Panagiotis, Gill, Jennifer, Kanavos, Panos (2025). HTA222 Life-years lost due to regulatory and reimbursement delays: a study of oncology drugs across England, Scotland, and France, 2022-2024. Value in Health, 28(12, Supplement 1), S448. https://doi.org/10.1016/j.jval.2025.09.2006
  • Eaves, Kristian, Mills, Mackenzie, Kanavos, Panos, Tolkmitt, Fiona, Alani, Ahmad Hecham (2025). HTA225 LLM engineering in HEOR: approaches to improving accuracy in clinical data extraction. Value in Health, 28(12, Supplement 1), S448 - S449. https://doi.org/10.1016/j.jval.2025.09.2009
  • Haig, Madeleine, Purohit, Divya, Main, Caitlin, Kanavos, Panos (2025). HTA241 Navigating clinical trial design under the EU Health Technology Assessment Regulation. Value in Health, 28(12, Supplement 1), S451. https://doi.org/10.1016/j.jval.2025.09.2024
  • Alani, Ahmad Hecham, Sharma, Abhinaw, Chellani, Lehar, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA27 Advocating from the margins: how patient input aligns with broader evidence tolerance in HTA within oncology. Value in Health, 28(12, Supplement 1), S405. https://doi.org/10.1016/j.jval.2025.09.1812
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA54 Beyond RCTs the role of patient perspectives and nontraditional evidence in HTA decisions for breast cancer (BC) and non-small cell lung cancer (NSCLC). Value in Health, 28(12, Supplement 1), S411. https://doi.org/10.1016/j.jval.2025.09.1839
  • Kanavos, Panos, Purohit, Divya, Chávez, Danitza, Kanavos, Leonidas (2025). HTA75 Clinical benefit vs. reimbursement decisions: examining misalignments between ESMO-MCBS and HTA outcomes in oncology. Value in Health, 28(12, Supplement 1), S416. https://doi.org/10.1016/j.jval.2025.09.1860
  • Alani, Ahmad Hecham, Focil, Diana Rebeca Acosta, Ecker, Hanne, Mills, Mackenzie, Kanavos, Panos (2025). HTA79 Comparative clinical effectiveness in skin cancer: lessons from HTA decision making in EU4, Uk, and Australia. Value in Health, 28(12, Supplement 1). https://doi.org/10.1016/j.jval.2025.09.1864
  • Therianos, Panagiotis, Kyriopoulos, Ilias-Ioannis, Kanavos, Panos (2025). HTA82 Comparing HTA outcomes and rationale for decision making between countries with mature vs. newly founded HTA systems: evidence from England, France, and Greece. Value in Health, 28(12, Supplement 1), S417 - S418. https://doi.org/10.1016/j.jval.2025.09.1867
  • Federico, Augustovski, Chávez, Danitza, Haig, Madeleine, Main, Caitlin, Argento, Fernando, Colaci, Carla, Mills, Mackenzie, Alfie, Verónica, Pichon Riviere, Andrés & Alcaraz, Andrea et al (2025). A Delphi study on valuing DNA sequencing in oncology: a European stakeholder developed framework for assessing next generation sequencing and comprehensive genomic profiling diagnostics. EBioMedicine, 121, https://doi.org/10.1016/j.ebiom.2025.105947 picture_as_pdf
  • Schätz, L., Goulart, M., Cirillo, R., Hernandez, D., Peristeris, P., Poschenrieder, A., Papaioannou, P., Kanavos, P., la Fougère, C., Holzwarth, U. (2025). 2305P Are European healthcare systems prepared for a potential rapid rise in radioligand therapy eligible patient numbers? Annals of Oncology, 36(Supplement 2), S1267. https://doi.org/10.1016/j.annonc.2025.08.2921
  • Candore, Gianmario, Martin, Claire, Mills, Mack J., Suter, Annabel, Lloyd, Anna, Chavez‐Montoya, Danitza, Civitelli, Diego, Wolf, Birgit, Bolot, Paul & Wasem, Juergen et al (2025). FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence uncertainties for efficacy/effectiveness – an evaluation of regulatory and health technology assessment decision making. Clinical Pharmacology and Therapeutics, 118(3), 649 - 661. https://doi.org/10.1002/cpt.3713 picture_as_pdf
  • Papadopoulos, Filippos, Visintin, Erica, Kyriopoulos, Ilias-Ioannis, Kanavos, Panos (2025). Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countries. Health Economics, Policy and Law, 20(3), 264 - 283. https://doi.org/10.1017/S1744133125100212 picture_as_pdf
  • Civitelli, Diego, Satish, Kavyashree, Kanavos, Panos (2025). HSD8 A case-study on the implementation of the Population Health Agreement for Inclisiran in England. Value in Health, 28(6, Supplement 1), S226. https://doi.org/10.1016/j.jval.2025.04.904
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanya, Lucy, Kanavos, Panos, Al-Omar, Hussain A. (2025). HTA23 Broadening the evidence base: incorporating environmental considerations Into HTAs. Value in Health, 28(6, Supplement 1), S251. https://doi.org/10.1016/j.jval.2025.04.1034
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024). Value in Health, 28(6, Supplement 1), S254. https://doi.org/10.1016/j.jval.2025.04.1054
  • Civitelli, Diego, Mills, Mackenzie, Kanavos, Panos (2025). HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28(6, Supplement 1), S259. https://doi.org/10.1016/j.jval.2025.04.1080
  • Bergsteedt, Matthew, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA92 Diffusion and launch sequencing of cell and gene therapies across the USA, Europe, Canada and Australia. Value in Health, 28(6, Supplement 1), S263 - S264. https://doi.org/10.1016/j.jval.2025.04.1103
  • Eaves, Kristian, Zaitceva, Viktoriia, Lin, Ryan, Mills, Mackenzie, Kanavos, Panos (2025). MSR17 A comparative assessment of LLM agreement for clinical data extraction tasks. Value in Health, 28(6, Supplement 1), S277. https://doi.org/10.1016/j.jval.2025.04.1170
  • Zaitceva, Viktoriia, Eaves, Kristian, Mills, Mackenzie, Kanavos, Panos (2025). P53 Alignment between CDA recommendations and pCPA negotiation outcomes: exploring factors influencing reimbursement success. Value in Health, 28(6, Supplement 1), S19. https://doi.org/10.1016/j.jval.2025.04.071
  • Main, Caitlin, Schafer, Cathrin, Kanavos, Panos (2025). From vision to reality: the EU's pharmaceutical reforms and the path to improved access. PHARMACOECONOMICS-OPEN, 9(3), 331 - 339. https://doi.org/10.1007/s41669-024-00556-w picture_as_pdf
  • Al-Omar, Hussain Abdulrahman, Almuhsin, Asma Abdulaziz, Almudaiyan, Lolwa Hamad, Al-Najjar, Amal Hassan, Abu Esba, Laila Carolina, Almodaimegh, Hind, Altawil, Esraa S., Yousef, Consuela Cheriece, Khan, Mansoor Ahmed & Alyahya, Khalid et al (2025). A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop. Journal of Medical Economics, 28(1), 753 - 765. https://doi.org/10.1080/13696998.2025.2506967 picture_as_pdf
  • Leon, Giovanny, Carbonel, Christophe, Rampuria, Aparajit, Singh Rajpoot, Ravindra, Joshi, Parth, Kanavos, Panos (2025). An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries. European Journal of Health Economics, 26(3), 513 - 536. https://doi.org/10.1007/s10198-024-01706-x picture_as_pdf
  • Zaitceva, V, Tan, I, Mills, M., Kanavos, P. (2024). HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA. Value in Health, 27(12, Supplement), S323 - S323. https://doi.org/10.1016/j.jval.2024.10.1677
  • Eaves, K., Lin, R., Alani, A. H., Mills, M., Kanavos, P. (2024). HTA117 Sentiment analysis of clinical evaluations in HTA: evidence from Canada, England, Scotland, Sweden, France, and Germany. Value in Health, 27(12, Supplement), S376 - S376. https://doi.org/10.1016/j.jval.2024.10.1942
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843
  • Eaves, K., Lin, R., Mills, M., Kanavos, Panos (2024). HTA201 A quantitative assessment of the economic decision drivers outlined in HTA outcomes through stratification and sentiment analysis: evidence from Canada, England, Scotland, and Sweden. Value in Health, 27(12 Supplement), S393 - S393. https://doi.org/10.1016/j.jval.2024.10.2026
  • Alani, A. H., Eaves, K., Mills, Mackenzie, Kanavos, P. (2024). HTA246 Improving access to innovative therapies for rare bleeding disorders: evidence from high income countries. Value in Health, 27(12), S402 - S403. https://doi.org/10.1016/j.jval.2024.10.2071
  • Tolkmitt, F., Chavez, D., Mills, M., Kanavos, P. (2024). HTA354 Determinants of added benefit ratings in Germany: an econometric analysis of assessments from the Federal Joint Committee between 2012 and 2024. Value in Health, 27(12 Supplement), S425 - S425. https://doi.org/10.1016/j.jval.2024.10.2179
  • Lin, R., Eaves, K., Mills, M., Kanavos, P. (2024). HTA64 Leveraging machine learning for predicting health technology assessment outcomes. Value in Health, 27(12, Supplement), S365 - S365. https://doi.org/10.1016/j.jval.2024.10.1889
  • Chavez, D., Tolkmitt, F., Mills, M., Kanavos, P. (2024). PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process. Value in Health, 27(12, Supplement), S323 - S323. https://doi.org/10.1016/j.jval.2024.10.3814
  • Kanavos, Panos, Visintin, Erica, Angelis, Aris (2024). Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis. The Lancet Oncology, 25(12), 1644 - 1654. https://doi.org/10.1016/S1470-2045(24)00505-9 picture_as_pdf
  • Candore, Gianmario, Martin, Claire, Gabarro, Montse Soriano, Mills, Mackenzie, Kanavos, Panos, Bromley, Susan, Cooper, Amy L., Wolf, Birgit, Bolot, Paul & Franklin, Joe et al (2024). Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs: evidence from North America, Europe, and Australia. Pharmacoepidemiology and Drug Safety, 33, 542 - 543. https://doi.org/10.1002/pds.5891
  • Leon, Giovanny, Gonzalez-Pier, Eduardo, Kanavos, Panos, Ruiz de Castilla, Eva Maria, Machinicki, Gerardo (2024). The 30-billion-dollar distribution markups and taxes of pharmaceuticals in Latin American countries: impact, options, and trade-offs. Value in Health Regional Issues, 44, https://doi.org/10.1016/j.vhri.2024.101015 picture_as_pdf
  • Augustovski, Federico, Colaci, Carla, Mills, Mackenzie, Chávez, Danitza, Argento, Fernando, Alfie, Verónica, Pichon Riviere, Andrés, Kanavos, Panos, Alcaraz, Andrea (2024). A systematic review of value criteria for next-generation sequencing/ comprehensive genomic profiling to inform value framework development. Value in Health, 27(5), 670 - 685. https://doi.org/10.1016/j.jval.2024.02.002 picture_as_pdf
  • Main, Caitlin, Haig, Madeleine, Chávez, Danitza, Kanavos, Panos (2024). Assessing the value of provider-facing digital health technologies used in chronic disease management:: toward a value framework based on multistakeholder perceptions. Medical Decision Making, 44(1), 28 - 41. https://doi.org/10.1177/0272989X231206803 picture_as_pdf
  • Gill, Jennifer L, Chávez, Danitza, Main, Caitlin, Miracolo, Aurelio, Kanavos, Panos (2023). HPR85 Opinions on sustainable healthcare financing options for funding new medical technologies in Asean-6. Value in Health, 26(12), S268 - S269. https://doi.org/10.1016/j.jval.2023.09.1403
  • Kanavos, Panos, Alcaraz, OA, Chávez, Danitza, Colaci, C, Haig, Madeleine, Argento, F, Main, Caitlin, Alfie, Verónica, Mills, Mackenzie & Pichon-Riviere, DA et al (2023). HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe: building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Value in Health, 26(12), S355 - S355. https://doi.org/10.1016/j.jval.2023.09.1870
  • Politopoulou, Konstantina, Mills, Mackenzie, Kanavos, Panos (2023). HTA255 First-in-class drugs in HTA blunder or bliss? Value in Health, 26(12), S369 - S369. https://doi.org/10.1016/j.jval.2023.09.1938
  • Gill, Jennifer L, Miracolo, Aurelio, Politopoulou, Konstantina, Jayawardana, Sahan, Apostolou, Efstratios A., Carter, Alex, Kanavos, Panos (2023). MSR1 Estimating lifetime benefits of optimizing secondary preventive treatment for atherosclerotic cardiovascular disease. Value in Health, 26(12), S393 - S393. https://doi.org/10.1016/j.jval.2023.09.2060
  • Main, Caitlin, Haig, Madeleine, Kanavos, Panos (2023). P36 Towards a collaborative value assessment framework for provider-facing digital health technologies used in chronic disease management: Findings and Implications. Value in Health, 26(12), S9 - S9. https://doi.org/10.1016/j.jval.2023.09.048
  • Fontrier, Anna-Maria, Kamphuis, Bregtje W., Kanavos, Panos (2023). How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe. European Journal of Health Economics, https://doi.org/10.1007/s10198-023-01637-z picture_as_pdf
  • Apostolou, Efstratios A., Fontrier, Anna Maria, Efthimiadis, Georgios K., Kastritis, Efstathios, Parissis, John, Kanavos, Panos (2023). The patient pathway in ATTR-CM in Greece and how to improve it: a multidisciplinary perspective. Hellenic Journal of Cardiology, 73(September–October 20), 73 - 80. https://doi.org/10.1016/j.hjc.2023.05.004 picture_as_pdf
  • Angelis, Aris, Montibeller, Gilberto Neto, Kanavos, Panos (2023). A structured methodology for essential medicines lists and health emergency stockpiles: experience with the Emergency Medicines Buffer Stock in the United Kingdom. Social Science and Medicine, 337, https://doi.org/10.1016/j.socscimed.2023.116236 picture_as_pdf
  • Mills, Mackenzie, Kanavos, Panos (2023). Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products: evidence from nine OECD countries. PharmacoEconomics - Open, 7(4), 553 - 565. https://doi.org/10.1007/s41669-023-00406-1 picture_as_pdf
  • Fontrier, Anna-Maria, Kanavos, Panos (2023). Do reimbursement recommendations by the Canadian Agency for Drugs and Technology in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario? Value in Health, 26(7), 1011 - 1021. https://doi.org/10.1016/j.jval.2023.02.013 picture_as_pdf
  • Haig, Madeleine, Main, C, Chavez, D, Kanavos, Panos (2023). Navigating the digital health landscape for chronic disease management: a value assessment framework for patient-facing technologies. Value in Health, 26(6), S8 - S8. https://doi.org/10.1016/j.jval.2023.03.048
  • Haig, Madeleine, Main, Caitlin, Chávez, Danitza, Kanavos, Panos (2023). A value framework to assess patient-facing digital health technologies that aim to improve chronic disease management: a Delphi approach. Value in Health, 26(10), 1474-1484. https://doi.org/10.1016/j.jval.2023.06.008 picture_as_pdf
  • Kanavos, Panos, Vandoros, Sotiris (2023). Road traffic mortality and economic uncertainty: evidence from the United States. Social Science & Medicine, 326, https://doi.org/10.1016/j.socscimed.2023.115891 picture_as_pdf
  • Mills, Mackenzie, Michaeli, Daniel, Miracolo, Aurelio, Kanavos, Panos (2023). Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Services Research, 23(1), p. 150. https://doi.org/10.1186/s12913-023-09095-2 picture_as_pdf
  • Efthymiadou, Olina, Kanavos, Panos (2022). Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries. BMC Health Services Research, 22(1). https://doi.org/10.1186/s12913-022-08437-w picture_as_pdf
  • Angelis, A., Mellerio, J. E., Kanavos, Panos (2022). Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet Journal of Rare Diseases, 17(1). https://doi.org/10.1186/s13023-022-02419-1 picture_as_pdf
  • Gill, Jennifer L, Mills, Mackenzie J, Wharton, George A, Kanavos, Panos (2022). The future of oncology policy. Journal of Cancer Policy, 34, https://doi.org/10.1016/j.jcpo.2022.100352 picture_as_pdf
  • Mills, Mackenzie, Kanavos, Panos (2022). How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Health Policy, 126(11), 1130 - 1143. https://doi.org/10.1016/j.healthpol.2022.08.005 picture_as_pdf
  • Kanavos, Panos, Vogelsang, Michelle, Haig, Madeleine, Kolovou, Vasiliki (2022). Challenges for health systems seeking to embrace virtual health care for population health. European Journal of Health Economics, 23(7), 1079 - 1083. https://doi.org/10.1007/s10198-022-01503-4 picture_as_pdf
  • Michaeli, Daniel Tobias, Mills, Mackenzie, Kanavos, Panos (2022). Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Applied Health Economics and Health Policy, 20(5), 757 - 768. https://doi.org/10.1007/s40258-022-00737-w picture_as_pdf
  • Michaeli, Daniel Tobias, Mills, Mackenzie, Michaeli, Thomas, Miracolo, Aurelio, Kanavos, Panos (2022). Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational New Drugs, 40(4), 798 - 809. https://doi.org/10.1007/s10637-022-01227-5 picture_as_pdf
  • Fontrier, Anna-Maria, Visintin, Erica, Kanavos, Panos (2022). Similarities and differences in Health Technology Assessment systems and implications for coverage decisions: evidence from 32 countries. PHARMACOECONOMICS-OPEN, 6(3), 315 - 328. https://doi.org/10.1007/s41669-021-00311-5 picture_as_pdf
  • Kamphuis, Bregtje W., Kanavos, Panos (2021). Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy OPEN, 2, https://doi.org/10.1016/j.hpopen.2021.100045 picture_as_pdf
  • Miracolo, Aurelio, Sophiea, Marisa, Mills, Mackenzie, Kanavos, Panos (2021). Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America. Health Policy and Planning, 36(5), 790 - 810. https://doi.org/10.1093/heapol/czaa168 picture_as_pdf
  • Efthymiadou, Olina, Kanavos, Panos (2021). Determinants of managed entry agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. International Journal of Technology Assessment in Health Care, 37(1). https://doi.org/10.1017/S0266462321000039 picture_as_pdf
  • Kanavos, Panos, Kamphuis, Bregtje W., Fontrier, Anna-Maria, Parkin, Georgia Colville, Saleh, Shadi, Akhras, Kasey S. (2020). Pricing of in-patent pharmaceuticals in the Middle East and North Africa is external reference pricing implemented optimally? Health Policy, 124(12), 1297 - 1309. https://doi.org/10.1016/j.healthpol.2020.07.017 picture_as_pdf
  • Angelis, Aris, Thursz, Mark, Ratziu, Vlad, O'Brien, Alistair, Serfaty, Lawrence, Canbay, Ali, Schiefke, Ingolf, Bana e Costa, João C., Lecomte, Pascal, Kanavos, Panos (2020). Early health technology assessment during nonalcoholic steatohepatitis drug development: a two-round, cross-country, multicriteria decision analysis. Medical Decision Making, 40(6), 830 - 845. https://doi.org/10.1177/0272989X20940672 picture_as_pdf
  • Angelis, Aris, Kanavos, Panos, Phillips, Lawrence D. (2020). ICER value framework 2020 update: recommendations on the aggregation of benefits and contextual considerations. Value in Health, 23(8), 1040 - 1048. https://doi.org/10.1016/j.jval.2020.04.1828 picture_as_pdf
  • Mills, Mackenzie, Kanavos, Panos (2020). Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy, 124(3), 239-251. https://doi.org/10.1016/j.healthpol.2019.12.002
  • Angelis, Aris, Linch, Mark, Montibeller, Gilberto, Molina Lopez, Maria Teresa, Zawada, Anna, Orzel, Kinga, Arickx, Francis, Espin, Jaime, Kanavos, Panos (2020). Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework. Social Science & Medicine, 246, https://doi.org/10.1016/j.socscimed.2019.112595 picture_as_pdf
  • Gill, Jennifer, Fontrier, Anna-Maria, Kyriopoulos, Dionysis, Kanavos, Panos (2019). Variations in external reference pricing implementation does it matter for public policy? European Journal of Health Economics, 20(9), 1375 - 1397. https://doi.org/10.1007/s10198-019-01100-y description
  • Fontrier, Anna-Maria, Gill, Jennifer, Kanavos, Panos (2019). International impact of external reference pricing should national policy makers care? European Journal of Health Economics, 20(8), 1147 - 1164. https://doi.org/10.1007/s10198-019-01083-w picture_as_pdf
  • Kanavos, Panos (2019). Does external reference pricing deliver what it promises? Evidence on its impact at national level. European Journal of Health Economics, 21(1), 129-151. https://doi.org/10.1007/s10198-019-01116-4 picture_as_pdf
  • Oliveira, Mónica D., Mataloto, Inês, Kanavos, Panos (2019). Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. European Journal of Health Economics, 20(6), 891-918. https://doi.org/10.1007/s10198-019-01052-3 picture_as_pdf
  • López-Bastida, Julio, Ramos-Goñi, Juan Manuel, Aranda-Reneo, Isaac, Taruscio, Domenica, Magrelli, Armando, Kanavos, Panos (2019). Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. Orphanet Journal of Rare Diseases, 14(1). https://doi.org/10.1186/s13023-019-1126-1 picture_as_pdf
  • Kanavos, Panos, Angelis, Aris, Drummond, Michael (2019). An EU-wide approach to HTA an irrelevant development or an opportunity not to be missed? European Journal of Health Economics, 20(3), 329-332. https://doi.org/10.1007/s10198-019-01037-2
  • López-Bastida, J., Ramos-Goñi, J. M., Aranda-Reneo, I., Trapero-Bertran, M., Kanavos, Panos, Rodriguez Martin, B. (2019). Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases? Health Policy, 123(2), 152-158. https://doi.org/10.1016/j.healthpol.2018.11.015
  • Visintin, Erica, Tinelli, Michela, Kanavos, Panos (2019). Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. Health Policy, 123(2), 118-129. https://doi.org/10.1016/j.healthpol.2018.08.019
  • Efthymiadou, Olina, Mossman, Jean, Kanavos, Panos (2018). Health related quality of life aspects not captured by EQ-5D-5L: results from an international survey of patients. Health Policy, https://doi.org/10.1016/j.healthpol.2018.12.003 picture_as_pdf
  • Wouters, Olivier J., Sandberg, Dale M., Pillay, Anban, Kanavos, Panos (2018). The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Social Science & Medicine, https://doi.org/10.1016/j.socscimed.2018.11.029 picture_as_pdf
  • Angelis, Aris, Kanavos, Panos (2018). Comment on: “Does MCDA trump CEA?”. Applied Health Economics and Health Policy, https://doi.org/10.1007/s40258-018-0445-z picture_as_pdf
  • Efthymiadou, Olina, Mossman, Jean, Kanavos, Panos (2018). Differentiation of health related quality of life outcomes between five disease areas; results from an international survey of patients. International Journal of Technology Assessment in Health Care, 34(5), 498-506. https://doi.org/10.1017/S0266462318000557 picture_as_pdf
  • Gill, Jennifer, Baiceanu, Andrei, Clark, Paul J, Langford, Andrew, Latiff, Julianah, Yang, Pei-Ming, Yoshida, Eric M, Kanavos, Panos (2018). Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncology, 14(17), 1701-1710. https://doi.org/10.2217/fon-2017-0715 picture_as_pdf
  • Tinelli, Michela, Efthymiadou, Olina, Mossman, Jean, Kanavos, Panos (2018). OP141 Patient relevant outcome measures as predictors of health care use in multiple sclerosis. International Journal of Technology Assessment in Health Care, 33(S1). https://doi.org/10.1017/S0266462317001970
  • Angelis, Aris, Lange, Ansgar, Kanavos, Panos (2018). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 19(1), 123-152. https://doi.org/10.1007/s10198-017-0871-0
  • Ferrario, Alessandra, Arāja, Diāna, Bochenek, Tomasz, Čatić, Tarik, Dankó, Dávid, Dimitrova, Maria, Fürst, Jurij, Greičiūtė-Kuprijanov, Ieva, Hoxha, Iris & Jakupi, Arianit et al (2017). The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. PharmacoEconomics, 35(12), 1271-1285. https://doi.org/10.1007/s40273-017-0559-4
  • Angelis, Aris, Montibeller, Gilberto, Hochhauser, Daniel, Kanavos, Panos (2017). Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 17(149). https://doi.org/10.1186/s12911-017-0524-3
  • Tinelli, Michela, Kanavos, Panos, Efthymiadou, Olina, Visintin, Erica, Grimaccia, Federico, Mossman, Jean (2017). Using IMPrESS to guide policy change in multiple sclerosis. Multiple Sclerosis Journal, 24(9). https://doi.org/10.1177/1352458517737388
  • Wouters, Olivier J., Kanavos, Panos, McKee, Martin (2017). Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. The Milbank Quarterly, 95(3), 554 - 601. https://doi.org/10.1111/1468-0009.12279
  • Angelis, Aris, Kanavos, Panos (2017). Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Social Science & Medicine, 188, 137-156. https://doi.org/10.1016/j.socscimed.2017.06.024
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Pringle, Edward, Kanavos, Panos (2017). Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina, 37(5), 886-895. https://doi.org/10.1097/IAE.0000000000001280
  • Angelis, Aris, Tordrup, David, Kanavos, Panos (2017). Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Global Policy, 8(S2), 7-22. https://doi.org/10.1111/1758-5899.12341
  • Wouters, Olivier J., Kanavos, Panos (2017). A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Services Research, 17(242), 1-7. https://doi.org/10.1186/s12913-017-2184-5
  • Kanavos, Panos, Wouters, Olivier J. (2017). Health care after the Great Recession: financing options for sustainable and high-quality health systems. Global Policy, 8(S2), 5-6. https://doi.org/10.1111/1758-5899.12389
  • Angelis, Aris, Kanavos, Panos, Montibeller, Gilberto (2017). Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Global Policy, 8(S2), 76-83. https://doi.org/10.1111/1758-5899.12387
  • Nicod, Elena, Jackson, Timothy L., Grimaccia, Federico, Angelis, Aris, Costen, Marc, Haynes, Richard, Hughes, Edward, Pringle, Edward, Zambarakji, Hadi, Kanavos, Panos (2016). Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. European Journal of Health Economics, 17(8), 991-999. https://doi.org/10.1007/s10198-015-0741-6
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, O., Visintin, E., Grimaccia, Federico, Mossman, J. (2016). PND27 – the Impress (International Multiple Sclerosis) study; results on the socio-economic burden, health related quality of life and experience of multiple sclerosis patients in France. Value in Health, 19(7), A429-A430. https://doi.org/10.1016/j.jval.2016.09.481
  • Mossman, J., Efthymiadou, O., Tinelli, Michela, Kanavos, Panos (2016). PRM164 - reconsidering EQ-5D; quality of life domains that are important for Multiple Sclerosis patients. Value in Health, 19(7), A387. https://doi.org/10.1016/j.jval.2016.09.231
  • Nicod, Elena, Kanavos, Panos (2016). Scientific and social value judgments for orphan drugs in health technology assessment. International Journal of Technology Assessment in Health Care, 32(4), 218-232. https://doi.org/10.1017/S0266462316000416
  • Tinelli, Michela, Kanavos, Panos, Mossman, J. (2016). Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey. Multiple Sclerosis Journal, 22(S3), 148-149. https://doi.org/10.1177/1352458516663081
  • Angelis, Aris, Kanavos, Panos (2016). Critique of the American Society of Clinical Oncology value assessment framework for cancer treatments: putting methodologic robustness first. Journal of Clinical Oncology, 34(24), 2935-2936. https://doi.org/10.1200/JCO.2015.64.9673
  • Berg Brigham, Karen, Darlington, Meryl, Wright, John S. F., Lewison, Grant, Kanavos, Panos, Durand-Zaleski, Isabelle (2016). Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. Health Research Policy and Systems, 14(1). https://doi.org/10.1186/s12961-016-0111-6
  • Mossman, Jean, Kanavos, Panos, Tinelli, Michela (2016). Changing the treatment paradigm in multiple sclerosis: are the attitudes of patients and physicians aligned? Neurology, 86(16 Sup), 1.356.
  • Angelis, Aris, Kanavos, Panos (2016). Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. PharmacoEconomics, 34(5), 435-446. https://doi.org/10.1007/s40273-015-0370-z
  • Nicod, Elena, Kanavos, Panos (2016). Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study. Health Policy, 120(1), 35-45. https://doi.org/10.1016/j.healthpol.2015.11.007
  • Angelis, Aris, Tordrup, David, Kanavos, Panos (2015). Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy, 119(7), 964-979. https://doi.org/10.1016/j.healthpol.2014.12.016
  • Wouters, Olivier J., O'Donoghue, Donal J., Ritchie, James, Kanavos, Panos, Narva, Andrew S. (2015). Early chronic kidney disease: diagnosis, management and models of care. Nature Reviews Nephrology, 11(8), 491-502. https://doi.org/10.1038/nrneph.2015.85
  • Tzouma, Victoria, Grepstad, Mari, Grimaccia, Federico, Kanavos, Panos (2015). Clinical, ethical, and socioeconomic considerations for prescription drug use during pregnancy in women suffering from chronic diseases. Therapeutic Innovation and Regulatory Science, 49(6), 947-956. https://doi.org/10.1177/2168479015589820
  • Ferrario, Alessandra, Kanavos, Panos (2015). Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Social Science & Medicine, 124, 39-47. https://doi.org/10.1016/j.socscimed.2014.11.003 picture_as_pdf
  • Wouters, Olivier J., Kanavos, Panos (2015). Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bulletin of the World Health Organization, 93(9), 606-613. https://doi.org/10.2471/BLT.14.148742
  • Kanavos, Panos, Angelis, Aris (2014). Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Pharmaceutical Medicine, online, https://doi.org/10.1007/s40290-014-0066-2
  • Tordrup, David, Tzouma, Victoria, Kanavos, Panos (2014). Orphan drug considerations in Health Technology Assessment ineight European countries. Rare Diseases and Orphan Drugs: An International Journal of Public Health, 1(3), 86-97.
  • Grimaccia, Federico, Kanavos, Panos (2014). Cost, outcomes, treatment pathways and challenges for diabetes care in Italy. Globalization and Health, 10(58). https://doi.org/10.1186/1744-8603-10-58
  • Vandoros, Sotiris, Kanavos, Panos (2014). Parallel trade and pharmaceutical prices: a game-theoretic approach and empirical evidence from the European Union. World Economy, 37(6), 856-880. https://doi.org/10.1111/twec.12063
  • Ferrario, Alessandra, Sautenkova, Nina, Bezverhni, Zinaida, Seicas, Rita, Habicht, Jarno, Kanavos, Panos, Safta, Vladimir (2014). An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice, 7(1), p. 4. https://doi.org/10.1186/2052-3211-7-4
  • Tordrup, David, Mossman, Jean, Kanavos, Panos (2014). Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? International Journal of Technology Assessment in Health Care, 30(01), 10-19. https://doi.org/10.1017/S0266462313000640
  • Kanavos, Panos (2014). Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States. Health Policy, 118(2), 229-241. https://doi.org/10.1016/j.healthpol.2014.08.005
  • Bertoldi, Andréa D., Kanavos, Panos, França, Giovanny V. A., Carraro, André, Tejada, Cesar Augusto, Hallal, Pedro C., Ferrario, Alessandra, Schmidt, Maria (2013). Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review. Globalization and Health, 9(1), p. 62. https://doi.org/10.1186/1744-8603-9-62
  • Tordrup, David, Angelis, Aris, Kanavos, Panos (2013). Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey. Applied Health Economics and Health Policy, 11(6), 639-652. https://doi.org/10.1007/s40258-013-0056-7
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Prevost, Andrew T., Simpson, Andrew R.H., Kanavos, Panos (2013). Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Retina, 33(10), 2012-2017. https://doi.org/10.1097/IAE.0b013e3182a6b3e2
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Prevost, Toby, Simpson, Andrew, Kanavos, Panos (2013). Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Retina, 33(6), 1099-1108. https://doi.org/10.1097/IAE.0b013e31828991d6
  • Kanavos, Panos, Ferrario, Alessandra, Vandoros, Sotiris, Anderson, Gerard F. (2013). Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Affairs, 32(4), 753-761. https://doi.org/10.1377/hlthaff.2012.0920
  • Tordrup, David, Ahmed, Waqas, Bukhari, Khalid Saeed, Kanavos, Panos (2013). Availability of medical supplies during the 2010 Pakistan floods. The Lancet Global Health, 1(1), e13-e14. https://doi.org/10.1016/S2214-109X(13)70040-8
  • Jackson, Timothy, Nicod, Elena, Simpson, Andrew, Angelis, Aris, Grimaccia, Federico, Kanavos, Panos (2013). Symptomatic vitreomacular adhesion. Retina, 33(8), 1503-1511. https://doi.org/10.1097/IAE.0b013e31829232fd
  • Vandoros, Sotiris, Kanavos, Panos (2013). The generics paradox revisited: empirical evidence from regulated markets. Applied Economics, 45(22), 3230-3239. https://doi.org/10.1080/00036846.2012.703313
  • Nicod, Elena, Kanavos, Panos (2012). Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy, 108(2-3), 167-177. https://doi.org/10.1016/j.healthpol.2012.09.012
  • Kanavos, Panos, Nicod, Elena (2012). What is wrong with orphan drug policies?: suggestions for ways forward. Value in Health, 15(8), 1182-1184. https://doi.org/10.1016/j.jval.2012.08.2202
  • Linertová, Renata, Serrano-Aguilar, Pedro, Posada-de-la-Paz, Manuel, Hens-Pérez, Manuel, Kanavos, Panos, Taruscio, Domenica, Schieppati, Arrigo, Stefanov, Rumen, Péntek, Márta & Delgado, Claudia et al (2012). Delphi approach to select rare diseases for a European representative survey: the BURQOL-RD study. Health Policy, 108(1), 19-26. https://doi.org/10.1016/j.healthpol.2012.08.001
  • Prinja, Shankar, Aggarwal, Arun Kumar, Kumar, Rajesh, Kanavos, Panos (2012). User charges in health care: evidence of effect on service utilization & equity from north India. Indian Journal of Medical Research, Supplement, 136, 868-876.
  • Prinja, Shankar, Kanavos, Panos, Kumar, Rajesh (2012). Health care inequities in north India: role of public sector in universalizing health care. Indian Journal of Medical Research, 136, 421-431.
  • Helfer, Ana Paula, Camargo, Aline Lins, Tavares, Noemia Urruth Leão, Kanavos, Panos, Bertoldi, Andréa Dâmaso (2012). Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público. Revista Panamericana de Salud Pública/Pan American Journal of Public Health, 31(3), 225-232.
  • Von der Schulenburg, Fritz, Vandoros, Sotiris, Kanavos, Panos (2011). The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Economics Review, 1(1), 1-8. https://doi.org/10.1186/2191-1991-1-18
  • Kanavos, Panos, Vandoros, Sotiris (2011). Determinants of branded prescription medicine prices in OECD countries. Health Economics, Policy and Law, 6(3), 1-31. https://doi.org/10.1017/S1744133111000090
  • Sorenson, Corinna, Kanavos, Panos (2011). Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Health Policy, 100(1), 43-50. https://doi.org/10.1016/j.healthpol.2010.08.001
  • Kanavos, Panos, Vandoros, Sotiris (2011). Drugs US: are prices too high?: measuring international pharmaceutical price differences. Significance, 8(1), 15-18. https://doi.org/10.1111/j.1740-9713.2011.00471.x
  • Kanavos, Panos, Gemmill-Toyama, Marin (2010). Prescription drug coverage among elderly and disabled Americans: can Medicare—Part D reduce inequities in access? International Journal of Health Care Finance and Economics, 10(3), 203-218. https://doi.org/10.1007/s10754-010-9077-z
  • Kanavos, Panos, Vandoros, Sotiris (2010). Competition in prescription drug markets: is parallel trade the answer? Managerial and Decision Economics, 31(5), 325-338. https://doi.org/10.1002/mde.1486
  • Lluch, Maria, Kanavos, Panos (2010). Impact of regulation of community pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Health Policy, 95(2-3), 245-254. https://doi.org/10.1016/j.healthpol.2009.11.002
  • Kanavos, Panos, Sullivan, R., Lewison, G., Schurer, W., Eckhouse, S., Vlachopioti, Z. (2010). The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience, 4, https://doi.org/10.3332/ecancer.2010.164
  • Geitona, Mary, Kanavos, Panos (2010). Colocteral cancer management and prevention policies in Greece. European Journal of Health Economics, 10(Supp.1), 27-33. https://doi.org/10.1007/s10198-009-0193-y
  • Schurer, Willemien, Kanavos, Panos (2010). Colorectal cancer management in the United Kingdom: current practice and challenges. European Journal of Health Economics, 10(Supp.1), 85-90. https://doi.org/10.1007/s10198-009-0202-1
  • Kanavos, Panos, Schurer, Willemien (2010). The burden of colorectal cancer: prevention, treatment and quality of services. European Journal of Health Economics, 10(Supp.1), 1-3. https://doi.org/10.1007/s10198-009-0200-3
  • Kanavos, Panos, Schurer, Willemien (2010). The dynamics of colorectal cancer management in 17 countries. European Journal of Health Economics, 10(Supp.1), 115-129. https://doi.org/10.1007/s10198-009-0201-2
  • Kanavos, Panos, Nicod, Elena, van den Aardweg, Stacey, Pomedli, Stephen (2010). The impact of health technology assessments: an international comparison. Euro Observer, 12(4), 1-7.
  • Sorenson, Corinna, Kanavos, Panos, Karamalis, M. (2009). HTA in Central and Eastern Europe: current status, challenges and opportunities. Journal of Medical Device Regulation, 6(1), 34-45.
  • Kanavos, Panos, Vandoros, Sotiris, Garcia-Gonzalez, Pat (2009). Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Globalization and Health, 5(19), 1-13. https://doi.org/10.1186/1744-8603-5-19
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos, McGuire, Alistair (2008). Does the work of the National Institute for Health and Clinical Excellence (NICE) have any relevance for the United States? ISPOR Connections, 14(4), 7-9.
  • Kanavos, Panos, Costa-i-Font, Joan, Seeley, Elizabeth (2008). Competition in off-patent drug markets: issues, regulation and evidence. Economic Policy, 23(55), 499-544. https://doi.org/10.1111/j.1468-0327.2008.00207.x
  • McGuire, Alistair, Raikou, Maria, Kanavos, Panos (2008). Pricing pharmaceuticals: value based pricing in what sense? Eurohealth, 14(2), 3-6.
  • Kanavos, Panos (2007). Do generics offer significant savings to the UK National Health Service? Current Medical Research and Opinion, vol. 23(1). Current Medical Research and Opinion, 23(1), 105-116. https://doi.org/10.1185/030079907X159506
  • Costa-i-Font, Joan, Kanavos, Panos, Rovira-Forns, Joan (2007). Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia. Applied Economics, 39(5), 541-551. https://doi.org/10.1080/00036840500438947
  • Costa-i-Font, Joan, Kanavos, Panos (2007). Importaciones paralelas de medicamentos: El caso de la Simvastaina en Alemania, Holanda y el Reino Unido. Gaceta Sanitaria, 21(1), 53-59.
  • Kanavos, Panos, Costa-i-Font, Joan, McGuire, Alistair (2007). Product differentiation, competition and regulation of new drugs: the case of statins in four European countries. Managerial and Decision Economics, 28(4-5), 455-465. https://doi.org/10.1002/mde.1354
  • Gemmill, Marin, Costa-i-Font, Joan, Kanavos, Panos (2006). Insurance coverage and the heterogeneity of health and drug spending in the United States. Geneva Papers on Risk and Insurance: Issues and Practice, 31(4), 669-691. https://doi.org/10.1057/palgrave.gpp.2510098
  • Morgan, S, McMahon, M, Mitton, C, Rougehead, E, Kirk, R, Kanavos, Panos, Menom, D (2006). Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Affairs, 25(2), 337-347. https://doi.org/10.1377/hlthaff.25.2.337
  • Kanavos, Panos, Saka, R (2006). Economic evaluation for orphan drugs: is it possible? Eurohealth,
  • Tatar, Mehtap, Kanavos, Panos (2006). Health care reform in Turkey: a dynamic path in the wake of political consensus. Eurohealth, 12(1), 20-22.
  • Kanavos, Panos, Yfantopoulos, J., Politis, C., Vandoros, C. (2006). The economics of blood: gift of life or a commodity? International Journal of Technology Assessment in Health Care, 22(3), 338-343. https://doi.org/10.1017/S0266462306051233
  • Kanavos, Panos (2006). The rising burden of cancer in the developing world. Annals of Oncology, 17(Supple). https://doi.org/10.1093/annonc/mdl983
  • Kanavos, Panos, Costa-i-Font, Joan (2005). Pharmaceutical parallel trade in Europe: stakeholders and competition effects. Economic Policy, 20(44), 751-798. https://doi.org/10.1111/j.1468-0327.2005.00150.x
  • Park, Sylvia, Ross-Degnan, Dennis, Adams, Alyce S, Sabin, James, Kanavos, Panos, Soumerai, Stephen B (2005). Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: a population-based study. British Journal of Psychiatry, 187(2), 137-142. https://doi.org/10.1192/bjp.187.2.137
  • Knapp, Martin, Kanavos, Panos, King, Derek, Yesudian, Hannah Monica (2005). Economic issues in access to medications: Schizophrenia treatment in England. International Journal of Law and Psychiatry, 28(5), 514-531. https://doi.org/10.1016/j.ijlp.2005.08.007
  • Costa-i-Font, Joan, Kanavos, Panos (2005). Efectos del comercio paralelo de medicamentos en la Unión Europea y evidencia de Alemania. Boletin de Estudios Economicos, 60(185), 251-263.
  • Kanavos, Panos, Saka, Ömer R (2005). How should functionally equivalent drugs be reimbursed? A retrospective analysis of reimbursement for Epoetin-[alpha] and Darbepoetin-[alpha] in 2001-2003 and the cost implications for CMS. Disease Management and Health Outcomes, 13(6), 359-370.
  • Kanavos, Panos, Saka, O (2005). How should functionally equivalent drugs be reimbursed?: A retrospective analysis of reimbursement for epoetin alfa and Darbepoetin alfa in 2001–3 and the cost implications for CMS. Disease Management and Health Outcomes, 13(6), 359-370.
  • Kanavos, Panos, Gemmill, M (2004). Senior citizens and the burden of prescription drug outlays: what lessons for the Medicare prescription drug benefit? Applied Health Economics and Health Policy, 3(4), 217-227.
  • Kanavos, Panos (2003). Reference pricing for drugs: is it compatible with US healthcare? Health Affairs, 22(3), 16-30. https://doi.org/10.1377/hlthaff.22.3.16
  • King, Derek R., Kanavos, Panos (2002). Encouraging the use of generic medicines: implications for transition economies. Croatian Medical Journal, 43(4), 462-469.
  • Kanavos, Panos (2002). EU pharmaceutical policy: the challenges and opportunities of enlargement. Eurohealth, 8(4), 24-26.
  • Kanavos, Panos, Trueman, P, Bosilevac, A (2000). Can economic evaluation guidelines improve efficiency in resource allocation? International Journal of Technology Assessment in Health Care, 16(4), 1179-1192.
  • Kanavos, Panos, McKee, Martin (2000). Cross-border issues in the provision of health services: are we moving towards a European health policy? Journal of Health Services Research and Policy, 5(4), 231-236.
  • Maynard, Alan, Kanavos, Panos (2000). Health economics: an evolving paradigm. Health Economics, 9(3), 183-190. https://doi.org/10.1002/(SICI)1099-1050(200004)9:3<183::AID-HEC515>3.0.CO;2-I
  • Kanavos, Panos (2000). Towards evidence-based decisions in health care: a prospective assessment of training needs in health economics and management in the European Union. Hepac Health Economics in Prevention and Care, 1(1), 78-90. https://doi.org/10.1007/s101980050018
  • Trueman, P., Kanavos, Panos, Wallace, M. (2000). The increasing use of economic evaluation of pharmaceuticals, part 1: guidelines for economic evaluation and their role in health policy. Clinical Research Focus, 11(1), 23-29.
  • Trueman, P., Kanavos, Panos, Wallace, M. (2000). The increasing use of economic evaluation of pharmaceuticals, part 2: 'the fourth hurdle': what does it mean for drug development? Clinical Research Focus, 11(2), 24-29.
  • Kanavos, Panos (2000). The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings. PharmacoEconomics, 18(6), 523-532.
  • Kanavos, Panos (1999). Financing pharmaceuticals in transition. Croatian Medical Journal, 40(June), 244-259.
  • Kanavos, Panos, Mossialos, Elias (1999). Outstanding regulatory issues in the European Union pharmaceutical market. PharmacoEconomics, 15(6), 519-533.
    • Book
  • Kanavos, Panos, Gemmill, Marin (2005). Pharmaceutical pricing and reimbursement in Europe. Scrip (Firm).
  • Kanavos, Panos, Ustel, Ismail, Costa-Font, Joan (2005). Türkiye'de ilaç geri ödeme politikası. Sağlıkta Umut Vakfı. https://doi.org/9750037014
    • Chapter
  • Cylus, Jonathan, Wouters, Olivier J., Kanavos, Panos (2015). Understanding the role of governance in the pharmaceutical sector: from laboratory to patient. In Greer, S., Wismar, M. & Figueras, J. (Eds.), Strengthening Health System Governance: Better Policies, Stronger Performance (pp. 175-187). Open University.
  • Kanavos, Panos, Wouters, Olivier J. (2014). Pharmaceutical parallel trade: legal, policy, and economic issues. In Culyer, A. J. (Ed.), Encyclopedia of health economics (pp. 20-28). Elsevier (Firm).
  • Kanavos, Panos (2004). European pharmaceutical policy and implications for current member States and pre-accession countries. In McKee, M. & McLehose, L. (Eds.), Health Policy and European Union Enlargement (pp. 240-264). Open University.
  • Kanavos, Panos, Soumerai, Stephen B, Ross-Degnan, Dennis (2004). Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector. In Mossialos, E., Mrazek, M. F. & Walley, T. (Eds.), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (pp. 97-113). Open University Press on behalf of the European Observatory on Health Systems and Policies.
  • Kanavos, Panos, Tatar, D, Taylor, D (2004). Regulating pharmaceutical distribution and retail pharmacy in Europe. In Mossialos, E., Mrazek, M. & Walley, T. (Eds.), Regulating Pharmaceuticals in Europe : Striving for Efficiency, Equity and Quality (pp. 196-212). Open University.
  • Kanavos, Panos (2003). Implications of financing systems. In Zollner, H., Stoddart, G. & Selby Smith, C. (Eds.), Learning to Live With Health Economics (pp. 69-86). World Health Organization. Regional Office for Europe.
  • Kanavos, Panos, Mossialos, Elias (2003). Managing healthcare reform: evaluation of available options. In Stoddart, G., Zollner, H. & Selby-Smith, C. (Eds.), Learning to Live With Healthcare Reform . World Health Organization. Regional Office for Europe.
  • Kanavos, Panos, Mossialos, Elias (2002). Evaluation of health care reform options. In Zollner, H., Stoddart, G. & Selby Smith, C. (Eds.), Learning to Live With Health Economics (pp. 37-48). World Health Organization. Regional Office for Europe.
    • Conference or Workshop Item
  • Tinelli, Michela, Efthymiadou, Olina, Mossman, Jean, Kanavos, Panos (2017-06-17 - 2017-06-21) PROMS as predictors of healthcare use in multiple sclerosis [Paper]. HTAiRome 2017, Rome, Italy, ITA.
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, Olina, Mossman, Jean (2016-10-29 - 2016-11-02) The IMPrESS (International Multiple Sclerosis Study);socio-economic burden, health related quality of life andexperiences of multiple sclerosis patients in France [Poster]. ISPOR 19th Annual European Congress, Vienna, Austria, AUT.
  • Efthymiadou, Olina, Tinelli, Michela, Mossman, Jean, Kanavos, Panos (2016-10-29 - 2016-11-02) Reconsidering EQ-5D; quality of life domains that are important for multiple sclerosis patients [Poster]. ISPOR 19th Annual European Congress, Vienna, Austria, AUT.
  • Mossman, Jean, Efthymiadou, Olina, Tinelli, Michela, Kanavos, Panos (2016-10-29 - 2016-11-02) Health related quality of life aspects not captured by EQ-5D-5L: results from the IMPrESS (International MultiPlE SclerosiS) study [Poster]. ISPOR 19th Annual European Congress, Vienna, Austria, AUT.
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, Olina, Visintin, Erica, Grimaccia, Federico, Mossman, Jean (2016-05-25) Social impact of MS – the family burden [Other]. Asociaţia Pacienţilor cu Afecţiuni Autoimune - "Scleroza Multiplă nu trebuie să fie o povară"/Patients with Autoimmune Disorders Association - "Multiple sclerosis should not be a burden", Bucharest, Romania, ROM.
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, Olina, Mossman, Jean (2016-05-10 - 2016-05-14) Moving towards better outcomes in Multiple Sclerosis by addressing policy change [Poster]. HTAi 2016 Annual Meeting - Informing Health Care Decisions with Values and Evidence, Tokyo, Japan, JPN.
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, Olina, Visintin, Erica, Grimaccia, Federico, Mossman, Jean (2016-05-17 - 2016-05-18) Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS) [Other]. European Multiple Sclerosis Platform (EMSP) Spring Conference 2016, Oslo, Norway, NOR.
  • Tinelli, Michela, Kanavos, Panos, Mossman, Jean (2016-09-14 - 2016-09-17) Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey [Poster]. ECTRIMS 2016 - 32nd Congress of the European committee for the treatment and research in multiple sclerosis, London, United Kingdom, GBR.
  • Kanavos, Panos, Tinelli, Michela, Mossman, Jean (2015-06-15 - 2015-06-17) Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey [Poster]. HTAi - Global Efforts in Knowledge Transfer: HTA to Health Policy and Practice, Oslo, Norway, NOR.
  • Tinelli, Michela, Kanavos, Panos, Winkler, Petr, Knapp, Martin, Höschl, Cyril, Pompili, Maurizio (2015-04-28 - 2015-04-30) The impact of non-treatment of schizophrenia in OECD countries: a literature review [Paper]. International Mental Health Congress (IMHC) - Mental Health for All: Connecting People and Sharing Experience, Lille, France, FRA.
  • Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Concurrence dans la distribution de produits pharmaceutiques [Paper]. OECD Forum Mondial sur la Concurrence, Paris, France, FRA.
  • Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Competition issues in the distribution of pharmaceuticals [Paper]. OECD Global Forum on Competition, Paris, France, FRA.
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos (2007-02-07 - 2007-02-08) Ensuring value for money in health care: The role of HTA in the European Union [Paper]. Financing sustainable healthcare in Europe: New approaches for new outcomes, Helsinki, Finland, FIN.
  • Kanavos, Panos (2002-09-23) Pharmaceutical regulation in Europe [Paper]. Institute for Research on Public Policy Conference – Toward a National Strategy on Drug Insurance: Challenges and Priorities, Toronto, Canada, CAN.
    • Dataset
  • Mills, Mackenzie, Kanavos, Panos, Michaeli, Daniel, Miracolo, Aurelio (2024). Additional file 1 of Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. [Dataset]. figshare. https://doi.org/10.6084/m9.figshare.26568085
  • Angelis, A., Kanavos, P., Mellerio, J. E. (2022). Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. [Dataset]. figshare. https://doi.org/10.6084/m9.figshare.c.6185650
  • Kanavos, Panos, Efthymiadou, Olina (2022). Additional file 1 of Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries. [Dataset]. figshare. https://doi.org/10.6084/m9.figshare.20522699
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Lopes Vieira, Ana, Dimitrovová, Klára, Bana e Costa, Carlos (2021). IMPACT HTA, WP7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 2 (Multi-criteria evaluation framework), Results of the 1st Web-Delphi process to HTA stakeholders, organized into 6 separate parallel panels. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5256671
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Lopes Vieira, Ana, Bana e Costa, Carlos (2021). IMPACT HTA, WP7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 2 (Multi-criteria evaluation framework), Results of the 2nd Web-Delphi process to HTA stakeholders, organized in a single panel. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5256844
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Bana e Costa, Carlos (2021). Results of the Web-Delphi process to INAMI stakeholders (three rounds). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5257297
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Bana e Costa, Carlos (2021). Results of the Web-Delphi process to YLV stakeholders (three rounds). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5257424
  • Visintin, Erica, Kanavos, Panos (2021). Determinants of HTA recommendations. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5222123
    • Report
  • Haig, Madeleine, Therianos, Panagiotis, Miracolo, Aurelio, Satish, Kavyashree, Kolovou, Vasiliki, Kanavos, Panos (2025). The burden of diabetes and options for reform: insights for the Greek health system. LSE Consulting. https://doi.org/10.21953/lse.3kihoqnmc1rv picture_as_pdf
  • Gill, Jennifer, Miracolo, Aurelio, Politopoulou, Konstantina, Jayawardana, Sahan, Carter, Alex, Apostolou, Efstratios A., Kanavos, Panos (2023). How can we improve secondary prevention of cardiovascular disease? Medical Technology Research Group (MTRG), The London School of Economics and Political Science. https://doi.org/10.21953/lse.f81e9y7znju1 picture_as_pdf
  • Gill, Jennifer, Chávez, Danitza, Main, Caitlin, Miracolo, Aurelio, Fontrier, Anna-Maria, Kanavos, Panos (2023). Sustainable healthcare financing for SDG3 in ASEAN-6. Medical Technology Research Group (MTRG), The London School of Economics and Political Science. https://doi.org/10.21953/lse.n02sh3yxlet8 picture_as_pdf
  • Main, Caitlin, Haig, Madeleine, Kanavos, Panos (2022). The promise of population health management in England: from theory to implementation. LSE Consulting. picture_as_pdf
  • Efthymiadou, Olina, Kamphuis, Bregtje, Gill, Jennifer, Haig, Madeleine, Kanavos, Panos (2022). Towards better outcomes in autism by addressing policy change. London School of Economics and Political Science. picture_as_pdf
  • Kamphuis, Bregtje, Fontrier, Anna-Maria, Haig, Madeleine, Politopoulou, Konstantina, Salyga, Hana, Gentilini, Arianna, Kanavos, Panos (2021). Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. LSE Consulting. picture_as_pdf
  • Kamphuis, Bregtje, Fontrier, Anna-Maria, Gill, Jennifer, Efthymiadou, Olina, Salyga, Hana, Kanavos, Panos (2021). Access to medicines in Europe delays and challenges for patient access: delays and challenges for patient access. LSE Consulting.
  • Kamphuis, Bregtje, Efthymiadou, Olina, Kanavos, Panos, Tzouma, Victoria (2021). Severe asthma care and treatment: indicators and data for performance management across ten countries. LSE Consulting. picture_as_pdf
  • Efthymiadou, Olina, Kamphuis, Bregtje, Kanavos, Panos, Tzouma, Victoria (2021). Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them: an international survey of clinicians. LSE Consulting. picture_as_pdf
  • Kamphuis, Bregtje, Gill, Jennifer, Vogelzang, Michelle, Haig, Madeleine, Kanavos, Panos (2021). The role of virtual health care and the pharmaceutical sector in improving population health. LSE Consulting.
  • Gill, Jennifer, Fontrier, Anna-Maria, Miracolo, Aurelio, Kanavos, Panos (2020). Access to personalised oncology in Europe.
  • Kanavos, Panos, Parkin, Georgia Colville, Kamphuis, Bregtje, Gill, Jennifer (2019). Latin America healthcare system overview: a comparative analysis of fiscal space in healthcare. LSE Consulting.
  • Kanavos, Panos, Mills, Mackenzie, Zhang, Anwen (2019). Pharmaceutical policy in China. LSE Consulting. https://doi.org/10.21953/lse.fg2t522b8r1x picture_as_pdf
  • Gill, Jennifer, Kanavos, Panos, d'Angela, Daniela, Berger, Karin, Dank, Magdolna, Duncombe, Robert, Fink-Wagner, Antje, Hutton, John, Kossler, Ingrid & Podrazilova, Katerina et al (2018). RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap. London School of Economics and Political Science. https://doi.org/10.21953/lse.anw9nzz3qqkp
  • Kanavos, Panos, Fontrier, Anna-Maria, Gill, Jennifer, Efthymiadou, Olina, Boekstein, Nicola (2017). The Impact of External Reference Pricing within and across Countries. London School of Economics and Political Science.
  • Kanavos, Panos, Fontrier, Anna-Maria, Gill, Jennifer, Kyriopoulos, Dionysis, Boekstein, Nicola (2017). The Implementation of External Reference Pricing within and across Country Borders. London School of Economics and Political Science.
  • Gill, Jennifer, Kanavos, Panos, Albanell, Joan, Dank, Magdolna, Duncombe, Robert, Fink-Wagner, Antje, Hutton, John, Jahnz-Różyk, Karina, Kossler, Ingrid & Podrazilova, Katerina et al (2017). RWE in Europe Paper II: The use of Real World Evidence in the disease context. London School of Economics and Political Science. https://doi.org/10.21953/LSE.RO.77037
  • Kanavos, Panos, Mills, Mackenzie, Cheatley, Jane, Lopez-Casasnovas, Guillem, Manganelli, Anton, Maynou, Laia, Serra, Miquel (2017). Controlling expenditure within the Spanish pharmaceutical market: macro- and micro-level policy approaches. LSE Health. https://doi.org/10.21953/LSE.RO.80113
  • Gill, Jennifer, Albanell, Joan, Avouac, Bernard, Berger, Karin, Boerlum Kristensen, Finn, Bucher, Heiner C., Duncombe, Robert, Fink-Wagner, Antje-Henriette, Hutton, John & Jahnz-Różyk, Karina et al (2017). RWE in Europe Paper III: A Roadmap for RWE. London School of Economics and Political Science.
  • Bonser, Andrew, Kanavos, Panos, Taylor, David (2016). Tender Loving Care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. London School of Economics and Political Science. https://doi.org/10.21953/LSE.RO.67824
  • Ferrario, Alessandra, Reinap, Marge, Pedersen, Hanne Bak, Kanavos, Panos (2016). Availability of medicines in Estonia: an analysis of existing barriers and options to address them. World Health Organization.
  • Kanavos, Panos, Tinelli, Michela, Efthymiadou, Olina, Visintin, Erica, Grimaccia, Federico, Mossman, Jean (2016). Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS). London School of Economics and Political Science.
  • Tinelli, Michela, Kanavos, Panos, Grimaccia, Federico (2016). The value of early diagnosis and treatment in Parkinson's disease: a literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease. London School of Economics and Political Science.
  • Ferrario, Alessandra, Kanavos, Panos, Humbert, Tifenn, Iwamoto, Kotoji, Bak Pedersen, Hanne (2016). Challenges and opportunities in improving access to medicines through efficient public procurement in WHO European Region. World Health Organization.
  • Gill, Jennifer, Kanavos, Panos, Avouac, Bernard, Duncombe, Robert, Hutton, John, Jahnz-Różyk, Karina, Schramm, Wolfgang, Spandonaro, Federico, Thomas, Michael (2016). The use of Real World Evidence in the European context: An analysis of key expert opinion. London School of Economics and Political Science.
  • Tinelli, Michela, Kanavos, Panos (2015). Cost and impact of non-treating severe mental illnesses (SMIs): the case study of schizophrenia. London School of Economics and Political Science.
  • Khan, Usman, Pallot, Robert, Taylor, David, Kanavos, Panos (2015). Transatlantic Trade and Investment Partnership: international trade law, health systems and public health. The London School of Economics and Political Science, Modus Europe.
  • Kanavos, Panos, Wouters, Olivier J. (2014). Pharmaceutical policies in Cyprus: a review of the current system and future options. World Health Organization.
  • Ferrario, Alessandra, Kanavos, Panos (2013). Managed entry agreements for pharmaceuticals: the European experience. EMiNet.
  • Sautenkova, Nina, Ferrario, Alessandra, Bolokhovets, Ganna, Kanavos, Panos (2012). Availability and affordability of medicines and assessment of quality systems for prescription of medicines in the Republic of Moldova: final report. (Health policy paper series no. 6). World Health Organization. Regional Office for Europe.
  • Kanavos, Panos, Schurer, Willemien, Vogler, Sabine (2011). The pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices. European Commission.
  • Kanavos, Panos, Nicod, Elena, Espin, Jaime, van den Aardweg, Stacey (2010). Short- and long-term effects of value-based pricingvs. external price referencing. EMiNet.
  • Kanavos, Panos, Vandoros, Sotiris, Irwin, Rachel, Nicod, Elena, Casson, Margaret (2010). The European pharmaceutical market and policies - outlook for the future. European Parliament.
  • Kanavos, Panos, Seeley, Elizabeth, Vandoros, Sotiris (2009). Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium. Enterprise and Industry, European Commission.
  • Kanavos, Panos, Vandoros, Sotiris, Habicht, Jarno, de Joncheere, Kees (2009). Review of the Estonian pharmaceutical sector: towards the development of a national medicines policy. World Health Organization. Regional Office for Europe.
  • Sorenson, Corinna, Kanavos, Panos (2009). Topic 1: financing medical devices in France and the UK. European Health Technology Institute on Socio-Economic Research.
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos, McGuire, Alistair (2008). National Institute for Health and Clinical Excellence (NICE). How does it work and what are the implications for the U.S? National Pharmaceutical Council.
  • Kanavos, Panos, Vandoros, Sotiris (2008). Validation of the Russian federal prescribing database and evaluation of policy outcomes. Russian Federal Bureau of Obligatory Medical Insurance.
  • Kanavos, Panos, Gross, David, Taylor, David (2005). Parallel trading in medicines: Europe’s experience and its implications for commercial drug importation in the United States. American Association for Retired Persons.
  • Kanavos, Panos, Costa-i-Font, Joan, Merkur, S., Gemmill, M. (2004). The economic impact of pharmaceutical parallel trade in European union member states: a stakeholder analysis. (Special Research Paper). London School of Economics and Political Science.
  • Kanavos, Panos, Holmes, P. R. (2004). Financial flows to global health partnerships. Department for International Development.
  • Kanavos, Panos, Lim, J Y, Pascual, C S (2002). On improving accessibility of drugs for the poor. (Philippines health policy note). World Bank.
  • Kanavos, Panos, Lim, J Y, Pascual, C S (2002). On improving the poor's access to affordable drugs. World Bank.
  • Exworthy, M., Kanavos, Panos (2001). Cross-border patient flows for health care in Europe: A feasibility study. U.K. Deapartment of Health.
  • Mossialos, Elias, Kanavos, Panos, Abel-Smith, B. (1994). Policy options for pharmaceutical research and development in the European Community. (Science and Technology Options Assessment Programme). European Parliament.
    • Other
  • Gill, J. L., Baiceanu, A., Clark, P., Langford, A., Latiff, J., Wilson, A., Yang, P-M., Yoshida, E., Kanavos, Panos (2016). HCC patient voices survey.
    • Online resource
  • Angelis, Aris, Kanavos, Panos (2015). Large scale mergers and acquisitions in the pharmaceutical industry: 1 + 1 = 1?
  • Wouters, Olivier J., Kanavos, Panos (2015). Primary health care should play bigger role in treating chronic kidney disease.
  • Ferrario, Alessandra, Kanavos, Panos (2013). The LSE Summit: risk sharing and managed entry agreements.
  • Ferrario, Alessandra, Kanavos, Panos (2013). Progress in addressing the growing diabetes epidemic is lagging behind due to poor control of the disease.
  • Kanavos, Panos (2013). Toward greater efficiency and equity in healthcare resource allocation: Dr Panos Kanavos to lead consortium in ADVANCE_HTA European Commission FP7 grant.
    • Working paper
  • Kanavos, Panos, Angelis, Aris (2013). Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework. (LSE Health working papers 33). LSE Health.
  • Kanavos, Panos, Schurer, Willemien, Owusu-Apenten, Candida, Sullivan, Richard (2008). Colorectal cancer in Europe and Australia: challenges and opportunities for the future. LSE Health, London School of Economics and Political Science.
  • Costa-i-Font, Joan, Kanavos, Panos (2007). Medicines in parallel trade in the European Union: a gravity specification. (LSE Health working papers 6/2007). London School of Economics and Political Science.
  • Kanavos, Panos, Ustel, I., Tatar, M., Costa-i-Font, Joan (2006). Health and drug sector reform in Turkey: caveats and opportunities. Health and Social Care, London School of Economics and Political Science.
  • Kanavos, Panos (2001). Overview of pharmaceutical pricing and reimbursement regulation. LSE Health.